News

Public · Published

Morgan Stanley maintains Cardinal Health at Overweight, raises price target to $286 from $265

Morgan Stanley kept its Overweight rating on Cardinal Health and raised its price target to $286 from $265, a 7.9% increase. The new target implies 13.9% upside from the October 29 close of $251.09.

Published:

Updated:

What happened

Morgan Stanley kept its Overweight rating on Cardinal Health and raised its price target to $286 from $265, a 7.9% increase. The new target implies 13.9% upside from the October 29 close of $251.09.

Confirmed

Global impact / market context

An Overweight rating means the analyst expects the stock to beat the broader market. A higher target signals greater expected profit, which can draw investor money into Cardinal Health shares and support the stock price.

Analyst inference

The target sits 13.9% above the last close, so the analyst sees room for gains. Research notes like this can shape investor positioning, because money managers often weigh analyst targets when deciding how much of a stock to hold.

Analyst inference

What to watch

  1. Watch whether other analysts change their Cardinal Health ratings or price targets after Morgan Stanley's move, since clustered revisions can reinforce or undercut the signal. Confirmed
  2. Track Cardinal Health's next quarterly results for revenue and costs, because actual profit growth would need to support the higher target over time. Proposed
  3. Watch the share price against the $286 target and the $251.09 reference close, since closing that gap would show whether investors accept the analyst's view. Analyst inference

Evidence

  • Original source link unavailable